1402838-08-7

Basic information

• Product Name: 2-(1-trityl-1H-imidazol-4-yl)benzaldehyde
• Synonyms: 2-(1-trityl-1H-imidazol-4-yl)benzaldehyde
• CAS NO: 1402838-08-7
• Molecular Formula: C₂₉H₂₂N₂O
• Molecular Weight: 414.49778
• EINECS: -0
• Mol File: 1402838-08-7.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Dichloromethane; Ethyl Acetate; Methanol
• CAS DataBase Reference: 2-(1-trityl-1H-imidazol-4-yl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-trityl-1H-imidazol-4-yl)benzaldehyde(1402838-08-7)
• EPA Substance Registry System: 2-(1-trityl-1H-imidazol-4-yl)benzaldehyde(1402838-08-7)

Safety Data

• Hazardous Substances Data: 1402838-08-7(Hazardous Substances Data)

Usage

Description

2-(1-trityl-1H-imidazol-4-yl)benzaldehyde is an organic compound that serves as a crucial intermediate in the synthesis of NLG919-d10 (N630002), which is an isotope-labelled analog of NLG919 (N630000). 2-(1-trityl-1H-imidazol-4-yl)benzaldehyde plays a significant role in the development of potent indoleamine-2,3-dioxygenase (IDO) pathway inhibitors, which are essential for addressing immunosuppression associated with cancer.

Uses

Used in Pharmaceutical Industry:
2-(1-trityl-1H-imidazol-4-yl)benzaldehyde is used as an intermediate in the synthesis of NLG919-d10 (N630002) for the development of potent indoleamine-2,3-dioxygenase (IDO) pathway inhibitors. These inhibitors are crucial in the treatment of immunosuppression associated with cancer, as they help modulate the immune response and improve the effectiveness of cancer therapies.
Used in Cancer Treatment:
2-(1-trityl-1H-imidazol-4-yl)benzaldehyde is used as a key component in the creation of IDO pathway inhibitors, which are essential for the treatment of various types of cancer. By targeting the IDO pathway, these inhibitors can help reduce immunosuppression and enhance the body's ability to fight cancer cells, leading to improved treatment outcomes for patients.
Used in Research and Development:
2-(1-trityl-1H-imidazol-4-yl)benzaldehyde is also used in research and development for the study of the IDO pathway and its role in cancer immunosuppression. 2-(1-trityl-1H-imidazol-4-yl)benzaldehyde can be utilized in the design and synthesis of new IDO inhibitors, contributing to the advancement of cancer treatment strategies and the development of more effective therapies.

Upstream product

• 40138-16-7 2-formylbenzene boronic acid 
• 96797-15-8 N-trityl-4⁽⁵⁾-iodoimidazole 
• 76-83-5 trityl chloride 
• 87941-55-7 4-bromo-1-(triphenylmethyl)-1H-imidazole 

Downstream Products

• 1402836-61-6 2-(5H-imidazo[5,1-α]isoindol-5-yl)-1-(2-nitrophenyl)ethanone 
• 1402836-82-1 1-cyclohexyl-2-[5H-imidazo[4,3-a]isoindol-5-yl]ethan-1-amine 
• 1402838-89-4 rac-1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanone 
• 1402836-58-1 rac-5-(2-hydroxyl(cyclohexylethyl))-5H-imidazo[5,1-a]isoindole 

Relevant articles and documents

Preparation method of (2-(1H-imidazole-4-yl)phenyl)methanol

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a preparation method of (2-(1H-imidazole-4-yl)phenyl)methanol. Amino of 4-iodine-1H-imidazole is protected by a triphenylmethyl protecting group and reacts wit

Discovery of clinical candidate (1 R,4 r)-4-((R)-2-((S)-6-Fluoro-5 H-imidazo[5,1-A[isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1

A novel class of 5-substituted 5H-imidazo[5,1-a]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). A structure-based drug design approach was used to elaborate the 5H-imidazo[5,1-a]isoindole core and to improve potency and pharmacological properties. Suitably placed hydrophobic and polar functional groups in the lead molecule allowed improvement of IDO1 inhibitory activity while minimizing off-target liabilities. Structure-activity relationship studies focused on optimizing IDO1 inhibition potency and a pharmacokinetic profile amenable to oral dosing while controlling CYP450 and hERG inhibitory properties.

A class of indoleamine 2,3-dioxygenase regulating compound and uses in pharmacy

The invention relates to compounds, which are one or a variety of inhibitors of indoleamine 2,3-dioxygenase. The invention further provides a pharmaceutical component containing the compound, a preparation containing the compound, and uses of the indoleamine 2,3-dioxygenase inhibitors, wherein the indoleamine 2,3-dioxygenase inhibitors can be separately used or can be combined with other drugs soas to treat symptoms related to indoleamine 2,3-dioxygenase.